Evidence map›Paper›PMID 42671493›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026

Predominance of M1

Shigeo Hanada, Misako Takata, Miyuki Baba-Morozumi, Junichi Sasaki, Satoshi Iwata, Shigeki Nakamura, Kimiko Ubukata

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shigeo Hanada *Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 105-8470, Japan. gourouhanada@yahoo.co.jp.ORCID https://orcid.org/0000-0002-8435-4425
Misako TakataDepartment of Microbiology, Tokyo Medical University, Tokyo, Japan.
Miyuki Baba-MorozumiDepartment of Microbiology, Tokyo Medical University, Tokyo, Japan.
Junichi SasakiDepartment of Emergency and Critical Care Medicine, Keio University School of Medicine, Tokyo, Japan.
Satoshi IwataDepartment of Microbiology, Tokyo Medical University, Tokyo, Japan.
Shigeki Nakamura *Department of Microbiology, Tokyo Medical University, Tokyo, Japan.
Kimiko Ubukata *Department of Microbiology, Tokyo Medical University, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe clinical relevance of M1

methodsWe conducted a nationwide multicenter surveillance study of iGAS infections from December 2023 to March 2025. Molecular typing, profiling of M1

resultsAmong 155 patients in the molecular epidemiology cohort, M1

conclusionM1

Indexed as

Invasive group A Streptococcus infectionM1UK typeMolecular epidemiologyNecrotizing fasciitisStreptococcal toxic shock syndromeStreptococcus pyogenes

Identifiers

PMID42671493

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.